{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:22:31Z","timestamp":1789024951843,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the safety and efficacy of bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>Two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials (RECONNECT) evaluated the safety and efficacy of bremelanotide 1.75 mg administered subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder. Patients were randomized 1:1 to 24 weeks of treatment with bremelanotide or placebo. Sample size was estimated based on simulations from key endpoints in patients with hypoactive sexual desire disorder from a prior trial. Coprimary efficacy endpoints were change from baseline to end-of-study in the Female Sexual Function Index\u2013desire domain score and Female Sexual Distress Scale\u2013Desire\/Arousal\/Orgasm item 13.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Study 301 began on January 7, 2015, and concluded on July 26, 2016. Study 302 began on January 28, 2015, and concluded on August 4, 2016. Of the 1,267 women randomized, 1,247 and 1,202 were in the safety and efficacy (modified intent-to-treat) populations, respectively. Most participants were white (85.6%), from U.S. sites (96.6%), and had a mean age of 39 years. From baseline to end-of-study, women taking bremelanotide had statistically significant increases in sexual desire (study 301: 0.30, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001; study 302: 0.42, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001; integrated studies 0.35, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001) and statistically significant reductions in distress related to low sexual desire (study 301: \u22120.37, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001; study 302: \u22120.29, <jats:italic toggle=\"yes\">P<\/jats:italic>=.005; integrated studies \u22120.33, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001) compared with placebo. Patients taking bremelanotide experienced more nausea, flushing, and headache (10% or more in both studies) compared with placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. The safety profile was favorable. Most treatment-emergent adverse events were related to tolerability and the majority were mild or moderate in intensity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT02333071 (study 301) and NCT02338960 (study 302).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>FUNDING SOURCE:<\/jats:title>\n            <jats:p>Palatin Technologies, Inc., and AMAG Pharmaceuticals, Inc.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003500","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T11:39:00Z","timestamp":1570707540000},"page":"899-908","source":"Crossref","is-referenced-by-count":134,"title":["Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder"],"prefix":"10.1097","volume":"134","author":[{"given":"Sheryl A.","family":"Kingsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita H.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johna","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230925","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jsxm.2016.09.020","article-title":"Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions\u2014part II","volume":"13","author":"Parish","year":"2016","journal-title":"J Sex Med"},{"key":"R3-20230925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","article-title":"Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review","volume":"92","author":"Goldstein","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R4-20230925","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1743-6109.2009.01252.x","article-title":"Correlates of sexually related personal distress in women with low sexual desire","volume":"6","author":"Rosen","year":"2009","journal-title":"J Sex Med"},{"key":"R5-20230925","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R7-20230925","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-015-0288-1","article-title":"The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder","volume":"29","author":"Kingsberg","year":"2015","journal-title":"CNS Drugs"},{"issue":"suppl 4","key":"R8-20230925","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1743-6109.2007.00610.x","article-title":"Bremelanotide: an overview of preclinical CNS effects on female sexual function","volume":"4","author":"Pfaus","year":"2007","journal-title":"J Sex Med"},{"key":"R9-20230925","doi-asserted-by":"crossref","first-page":"10201","DOI":"10.1073\/pnas.0400491101","article-title":"Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist","volume":"101","author":"Pfaus","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-20230925","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2003.tb03167.x","article-title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","volume":"994","author":"Molinoff","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R11-20230925","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/whe-2016-0018","article-title":"Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial","volume":"12","author":"Clayton","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"R12-20230925","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/0022-006X.47.2.343","article-title":"Assessment of suicidal intention: the scale for suicide ideation","volume":"47","author":"Beck","year":"1979","journal-title":"J Consult Clin Psychol"},{"key":"R13-20230925","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/713847100","article-title":"Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder","volume":"29","author":"Meston","year":"2003","journal-title":"J Sex Marital Ther"},{"key":"R14-20230925","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"R15-20230925","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1743-6109.2007.00672.x","article-title":"Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder","volume":"5","author":"DeRogatis","year":"2008","journal-title":"J Sex Med"},{"key":"R17-20230925","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/00926230290001448","article-title":"The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women","volume":"28","author":"DeRogatis","year":"2002","journal-title":"J Sex Marital Ther"},{"key":"R18-20230925","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/npp.2010.81","article-title":"How placebos change the patient's brain","volume":"36","author":"Benedetti","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R20-20230925","article-title":"U.S. Food and Drug Administration. Summary review for regulatory action"},{"key":"R21-20230925"},{"key":"R22-20230925","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881107076996","article-title":"An effect-size analysis of pharmacologic treatments for generalized anxiety disorder","volume":"21","author":"Hidalgo","year":"2007","journal-title":"J Psychopharmacol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T22:00:13Z","timestamp":1695679213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003500"}},"subtitle":["Two Randomized Phase 3 Trials"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003500","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}